Huangqintang， with its accurate efficacy， is a classic formula specialized in treating dysentery recommended and promoted by medical experts from successive generations， and it was included in the Catalogue of Ancient Classic Prescriptions （the Second Batch， Han Chinese medicine prescriptions） published by the National Administration of Traditional Chinses Medicine （TCM） in 2023. The method of bibliometrics was applied in this study to conduct textual research on the classic formula Huangqintang and provide a literature reference for the development of modern preparations of Huangqintang. A total of 2 026 pieces of ancient literature were searched with "Huangqintang" as the key word， and 23 pieces of effective data were selected， involving 15 ancient TCM books. The historic evolution， composition， dosage， origin， processing methods， preparation and decocting methods， efficiency， and application of Huangqintang were carefully reviewed. The results showed that Huangqintang was first recorded in the Treatise on Febrile Diseases written by ZHANG Zhongjing. It has the effect of clearing heat， stopping dysentery， regulating the middle， and downbearing counterflow and has become one of the classic formulas widely used in clinical practice. Because of its accurate efficacy， medical experts from later generations have modified it from its original composition. Though many prescriptions have different names， it is the manifestation of physicians' inheritance and development of the thought of ZHANG Zhongjing. Ancient literature showed this prescription had wide indications yet centered on digestive system diseases such as dysentery and abdominal pain. Modern applications of Huangqintang involve digestive， respiratory， ophthalmology and otolaryngology， gynecological， skin， musculoskeletal system， and connective tissue， and this prescription has great potential in treating ulcerative colitis， diarrhea， acute enteritis， and damp-heat dysentery. Through a systematic textual excavation and review of the ancient literature about Huangqintang， the paper has confirmed its key information， so as to provide a scientific basis for the clinical application and new drug development of classic formulas.

Objective:To investigate the incidence, risk factors, and bile acid profile characteristics of Crohn's disease (CD) patients complicated by gallstones.Methods:A retrospective observational study was conducted. Clinical data of CD patients admitted to Zhongda Hospital of Southeast University from January 2020 to December 2023 were collected. Patients were divided into the gallstone group and the non-gallstone group according to the presence of gallstones. Univariate analysis and Logistic multivariate analysis were perfomed to identify the risk factors of CD patients complicated by gallstones. Sixty-eight CD patients in remission were selected, and serum levels of 15 bile acids were compared between patients with and without gallstones.Results:A total of 296 CD patients were enrolled, including 211 males and 85 females, with a mean age of 37.8 ± 14.8 years, disease duration of 2.0 (1.0, 6.0) years, Crohn's disease activity index of 265.3 ± 121.2, and body mass index of 22.4±2.2 kg/m 2. Among them, 44 patients (14.9%) had gallstones and were assigned to the gallstone group, while the remaining 252 patients (85.1%) were assigned to the non-gallstone group. Univariate analysis and multivariate Logistic regression analysis showed that location was an independent risk factor for CD patients complicated by gallstones. Patients with ileocolonic CD have a 3.92-fold higher risk of developing gallstones than those with colonic CD ( OR=3.92, 95% CI: 1.13-13.61, P = 0.031). Analysis of bile acid profiles in 68 CD patients in remission revealed that, compared to those without gallstones ( n = 50), patients with gallstones ( n = 18) had lower levels of ursodeoxycholic acid and an higher ratio of secondary conjugated bile acid/secondary free bile acid, the differences were significant (both P < 0.05) . Conclusions:CD patients have a high incidence of gallstones, which may be associated with abnormal bile acid metabolism. The ileocolonic CD patients are more prone to developing gallstones.

Objective:To investigate the incidence, risk factors, and bile acid profile characteristics of Crohn's disease (CD) patients complicated by gallstones.Methods:A retrospective observational study was conducted. Clinical data of CD patients admitted to Zhongda Hospital of Southeast University from January 2020 to December 2023 were collected. Patients were divided into the gallstone group and the non-gallstone group according to the presence of gallstones. Univariate analysis and Logistic multivariate analysis were perfomed to identify the risk factors of CD patients complicated by gallstones. Sixty-eight CD patients in remission were selected, and serum levels of 15 bile acids were compared between patients with and without gallstones.Results:A total of 296 CD patients were enrolled, including 211 males and 85 females, with a mean age of 37.8 ± 14.8 years, disease duration of 2.0 (1.0, 6.0) years, Crohn's disease activity index of 265.3 ± 121.2, and body mass index of 22.4±2.2 kg/m 2. Among them, 44 patients (14.9%) had gallstones and were assigned to the gallstone group, while the remaining 252 patients (85.1%) were assigned to the non-gallstone group. Univariate analysis and multivariate Logistic regression analysis showed that location was an independent risk factor for CD patients complicated by gallstones. Patients with ileocolonic CD have a 3.92-fold higher risk of developing gallstones than those with colonic CD ( OR=3.92, 95% CI: 1.13-13.61, P = 0.031). Analysis of bile acid profiles in 68 CD patients in remission revealed that, compared to those without gallstones ( n = 50), patients with gallstones ( n = 18) had lower levels of ursodeoxycholic acid and an higher ratio of secondary conjugated bile acid/secondary free bile acid, the differences were significant (both P < 0.05) . Conclusions:CD patients have a high incidence of gallstones, which may be associated with abnormal bile acid metabolism. The ileocolonic CD patients are more prone to developing gallstones.

Crohn′s disease (CD) is an autoimmune disease that mainly affects the digestive tract. Rectal and perianal involvement is a complex manifestation of CD. Refractory proctoanal type CD is the main cause of rectal resection and permanent anal dysfunction. Recently, our center performed modified Bacon surgery in two CD patients with complex rectoperineal and rectovaginal fistulas who were about to undergo rectotomy and enterostomy. The data of these two cases are summarized and reported.

Crohn′s disease (CD) is an autoimmune disease that mainly affects the digestive tract. Rectal and perianal involvement is a complex manifestation of CD. Refractory proctoanal type CD is the main cause of rectal resection and permanent anal dysfunction. Recently, our center performed modified Bacon surgery in two CD patients with complex rectoperineal and rectovaginal fistulas who were about to undergo rectotomy and enterostomy. The data of these two cases are summarized and reported.

ObjectiveTo investigate the regulatory effect and molecular mechanism of berberine （BBR） on lipophagy in the prevention and treatment of atherosclerotic （AS） lesions in mice. MethodFifty apolipoprotein E-knockout （ApoE^-/-） mice were randomly divided into an AS model group， an atorvastatin group （5 mg·kg^-1）， and low-， medium-， and high-dose BBR groups （2.5， 5， 10 mg·kg^-1）. Ten C57BL/6J mice were assigned to the control group. After 12 weeks， hematoxylin-eosin （HE） and oil red O staining were performed to assess the histopathological changes of AS plaques in the aorta. Biochemical analysis was used to measure serum lipid levels， and enzyme-linked immunosorbent assay （ELISA） was employed to measure the levels of inflammatory cytokines interleukin-6 （IL-6） and tumor necrosis factor-α （TNF-α）， oxidative stress marker reactive oxygen species （ROS）， and serum lipophagy marker Beclin1 and microtubule-associated protein 1 light chain 3 Ⅱ （LC3Ⅱ）. The xanthine oxidase method was used to measure serum superoxide dismutase （SOD） activity. Immunohistochemistry （IHC） was used to detect the distribution of wingless-type MMTV integration site family member 5a （Wnt5a） and Nieman Pick type C1 （NPC1） in the aorta， and Western blot was used to determine the protein expression of Wnt5a and NPC1 in the aorta. ResultCompared with the control group， the AS model group showed significant AS plaque formation， significantly elevated levels of serum total cholesterol （TC）， triglycerides （TG）， low-density lipoprotein cholesterol （LDL-C）， IL-6， TNF-α， and ROS， aortic Wnt5a distribution and protein expression （P<0.01）， and significantly reduced levels of serum high-density lipoprotein cholesterol （HDL-C）， SOD， Beclin1， LC3Ⅱ， and aortic NPC1 distribution and protein expression （P<0.01）. Compared with the AS model group， the atorvastatin group， and high- and medium-dose BBR groups showed a significant reduction in AS plaque area （P<0.05， P<0.01）， significantly decreased levels of serum TC， TG， LDL-C， IL-6， TNF-α， ROS， and aortic Wnt5a distribution and protein expression （P<0.05， P<0.01）， and significantly increased levels of serum HDL-C， SOD， Beclin1， LC3Ⅱ， and aortic NPC1 distribution and protein expression （P<0.05， P<0.01）. There was no statistically significant difference in the above indicators between the atorvastatin group and the medium-dose BBR group. ConclusionBBR can competitively bind to Wnt5a to activate NPC1 expression， upregulate lipophagy levels， reduce blood lipids， and inhibit the release of inflammatory mediators and oxidative stress damage， thereby exerting a preventive and therapeutic effect on AS.